Alk-Abello As B Shs New (AKBLF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone, and welcome to this presentation of ALK's Q1 results. Thank you all for joining us. Let's turn to Slide number two with an introduction to the speakers and the agenda. My name is Peir Flonnikov. I'm Head of Investor Relations. And with me are CEO, Peter Helling and CFO, Claus Stings and Solvio. Peter and Claus will walk you through the highlights, markets, product trends and financial. And after a strategic update, where we'll focus on peanut allergy, our respiratory tablets and the Nephi rollout, we will turn to the full year outlook. As usual, we will end the call with a Q and A session. And to get started, I'll hand you over to Peter on Slide three. Please go ahead, Peter. Thank you, Peter. Thank you all for taking the time to listen into this call. Alk had a very solid start to the year with revenue and earnings comfortably exceeding the upper end of the full year guidance range. EBIT grew by 22%, yielding a margin of 32% on the back of an 18% revenue growth to DKK1.8 billion. For the first time ever, ALK's total tablet sales exceeded 1,000,000,000 in a single quarter. The results were furthermore supported by an improved gross margin, reflecting some seasonality in the sales mix with a relatively high proportion of European tablet states which carry higher margins. As guided, we expect this to somewhat normalize over the year as partner related revenue increases. On the strategic side, the pediatric tablets are now marketed in the majority of our key European and North American geographies and they're increasingly contributing to the inflow of new patients. Anaphylaxis sales also performed well, especially supported by JEGST. It is still early days regarding neficils, but we continue to develop market access and we have secured further regulator...